NKGen Biotech Inc. · OTC:NKGN

NKGen Biotech Inc. financial statements

NKGen Biotech Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2023FY2022FY2021
Revenue077.0K426.0K
Cost of revenue1.20M18.0K30.0K
Gross profit-1.20M59.0K396.0K
Research and development10.7M15.7M16.7M14.7M
Selling, general and administrative16.3M14.1M7.66M7.58M
Operating income-27.0M-29.7M-24.3M-21.9M
Depreciation and amortization1.31M1.20M1.21M1.24M
EBITDA-25.7M-28.5M-23.1M-20.6M
Interest expense2.72M745.0K2.31M1.31M
Income before tax-44.2M-82.9M-26.7M-23.3M
Income tax53.0K7.00K7.00K5.00K
Net income-44.3M-83.0M-26.8M-23.3M
Earnings per share, basic-1.54-5.38-1.25-1.08

Balance sheet

LineFY2025FY2023FY2022FY2021
Cash and equivalents26.0K117.0K351.0K
Receivables24.0K26.0K96.0K67.0K
Inventory-250.0K133.0K172.0K
Current assets24.0K1.93M350.0K612.0K
Property, plant and equipment15.9M17.4M
Total assets24.0K16.5M16.3M18.1M
Accounts payable11.0M975.0K1.71M
Current liabilities39.5M14.7M55.7M
Long-term debt9.93M
Total debt19.9M12.0M52.0M
Total liabilities75.2M14.8M56.1M
Shareholders' equity-58.7M1.56M-38.1M
Shares outstanding28.8M15.4M21.5M21.5M

Cash flow

LineFY2025FY2023FY2022FY2021
Cash from operations-20.9M-21.9M-22.6M-19.5M
Capital spending0-48.0K-163.0K-459.0K
Free cash flow-20.9M-22.0M-22.7M-20.0M
Cash from investing-13.0K-48.0K-163.0K-459.0K
Cash from financing20.9M22.2M22.5M20.2M
Change in cash1.70M159.0K-234.0K152.0K